Physician profile
Anna Kochin
NPI 1487804019
$6,582.15
in general payments reported to CMS, 2019-2025
33 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $2,881 · 2021: $369 · 2022: $798 · 2023: $536 · 2024: $487 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.92 |
| Education | $155.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,528.10 | 2019-2020 | |
| Genzyme Corporation | $1,126.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $671.00 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $559.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $340.50 | 2020-2024 | Tezspire, Fasenra |
| Optinose US, INC. | $128.86 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.43 | 2019-2021 | |
| Pfizer INC. | $116.44 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.50 | 2021-2024 | Hyqvia, Takhzyro, Cuvitru |
| Csl Behring | $113.02 | 2023-2025 | Andembry, Kcentra |
| Alk-Abello, INC | $88.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $70.44 | 2019-2025 | |
| Incyte Corporation | $68.48 | 2025 | Opzelura |
| Pharming Healthcare, INC. | $52.98 | 2023-2025 | Ruconest |
| Amarin Pharma, INC. | $43.68 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.46 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $36.81 | 2025 | Orladeyo |
| Phadia US INC. | $35.10 | 2021-2025 | Immunocap |
| Genentech USA, INC. | $33.76 | 2025 | Xolair |
| Exact Sciences Corporation | $25.03 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $24.58 | 2024 | |
| Nevro Corp. | $23.70 | 2022 | |
| Galderma Laboratories, L.P. | $22.09 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $21.95 | 2025 | Neffy |
| Novo Nordisk INC | $21.85 | 2024 | Ozempic, Rybelsus |
| Hikma Pharmaceuticals USA | $21.41 | 2022 | |
| Merck Sharp & Dohme LLC | $21.07 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.56 | 2022 | |
| Leo Pharma INC. | $19.32 | 2025 | Anzupgo |
| Shield Therapeutics INC | $18.98 | 2025 | |
| Grifols USA, LLC | $15.47 | 2025 | Xembify |
| Ultragenyx Pharmaceutical INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kochin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.